Promising lyme vaccine moves to final testing phase

NCT ID NCT07226882

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new Lyme disease vaccine (VLA15) in about 200 healthy adults aged 18 to 44. Participants receive five shots over two years—four of the vaccine and one of salt water—to see if different timing schedules are safe and produce a strong immune response. The goal is to find the best way to protect people from Lyme disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYME BORRELIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lyme Neuroborreliosis Lyme disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYME BORRELIOSIS LYME DISEASE

Contacts and locations

Locations

IMA Clinical Research Warren

Warren Township, New Jersey, 07059, United States
Northeast Clinical Trials Group

Scranton, Pennsylvania, 18510, United States
Preferred Primary Care Physicians

Uniontown, Pennsylvania, 15401, United States
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

Pittsburgh, Pennsylvania, 15236, United States
Smith Allergy & Asthma Specialists

Horseheads, New York, 14845, United States
Smith Allergy and Asthma Specialists

Cortland, New York, 13045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.